AMGN Stock Analysis & IQ Rating | Amgen

 Earnings are forecast to grow

 Trading below its fair value

 Upgraded on attractively valued

 Outperform the market

Strong Results and Pipeline Momentum Power Amgens (AMGN) 2025 Rally. Amgen Inc. (NASDAQ:AMGN) is included among the 14 Best Pharma Dividend Stocks to Buy in 2026. Amgen Inc. (NASDAQ:AMGN) has outperformed the broader market this year supported by strong financial results and steady clinical progress even as investors keep an eye on upcoming patent expirations. The stock is up more than 27% since the start [….]

Tue Dec 30, 2025

Amgen Inc. (AMGN) Is a Trending Stock: Facts to Know Before Betting on It. Amgen (AMGN) has received quite a bit of attention from Zacks.com users lately. Therefore it is wise to be aware of the facts that can impact the stocks prospects.

Mon Dec 29, 2025

Amgen Strikes Drug Pricing Deal With Trump: What Investors Should Know. AMGN signs a pricing deal with the Trump administration cutting United States drug costs expanding DTC access and securing tariff relief tied to domestic investment.

Wed Dec 24, 2025

Fitch upgrades Amgen to BBB on improved financial structure.

Mon Dec 22, 2025

Drug Sector on a High as 9 Drugmakers Strike Drug Pricing Deals. Amgen and eight other pharma giants struck deals with the Trump administration to cut United States drug prices while gaining tariff relief and manufacturing incentives.

Mon Dec 22, 2025

Takedas Once-Daily Psoriasis Pill Hits Phase 3 Goals Beats Amgens Drug. ).The studies demonstrated superiority of zasocitinib compared to placebo for the co-primary endpoints static Physician Global Assessment (sPGA) 0/1 and Psoriasis Area and Severity Index (PASI) 75 at week 16 with a significantly greater PASI 75 response rate seen as early as week 4 and continuing to .The studies also met all 44 ranked secondary endpoints including PASI 90 PASI 100 and sPGA 0 against placebo and ) Otezla (apr

Thu Dec 18, 2025

HSBC Turns More ish on Amgen (AMGN) into 2026. Amgen Inc. (NASDAQ:AMGN) is included among the 12 Best Dogs of the Dow to Invest in. On December 8 HSBC lifted its price target on Amgen Inc. (NASDAQ:AMGN) to $425 from $381. The firm also retained a Buy rating. The call came as part of the firms 2026 outlook for the pharma sector. HSBC sees [….]

Wed Dec 17, 2025

Amgen (AMGN) Price Target Trimmed at Morgan Stanley as Policy Risks Ease. Amgen Inc. (NASDAQ:AMGN) is included among the 15 Best Blue-Chip Stocks with Growing Dividends. On December 12 Morgan Stanley cut its price target for Amgen Inc. (NASDAQ:AMGN) from $329 to $304 but kept its Equal Weight rating. The firms 2026 biopharma outlook sounds more optimistic noting that a lot of the policy headaches that dragged [….]

Tue Dec 16, 2025

Amgen (AMGN) Rises As Market Takes a Dip: Key Facts. The latest trading day saw Amgen (AMGN) settling at $325.31 representing a 2.38% change from its previous close.

Mon Dec 15, 2025

FDA Approves Amgens Drug For Rare Muscle Disorder. The United States Food and Drug Administration (FDA) on Thursday approved ) Uplinza (inebilizumab-cdon) for .The approval covers adult patients who are anti-acetylcholine receptor (AChR) and anti-muscle-specific tyrosine kinase (MuSK) antibody positive.gMG is a rare chronic B-cell-mediated autoimmune disorder that impairs neuromuscular communication and can cause fluctuating muscle weakness.This is the third indication for Uplinza.The approval o

Fri Dec 12, 2025